NO944704L - Tiazolidinderivater og farmasöytiske blandinger som inneholder disse - Google Patents

Tiazolidinderivater og farmasöytiske blandinger som inneholder disse

Info

Publication number
NO944704L
NO944704L NO944704A NO944704A NO944704L NO 944704 L NO944704 L NO 944704L NO 944704 A NO944704 A NO 944704A NO 944704 A NO944704 A NO 944704A NO 944704 L NO944704 L NO 944704L
Authority
NO
Norway
Prior art keywords
group
compound
individually represent
atom
thiazolidin
Prior art date
Application number
NO944704A
Other languages
English (en)
Other versions
NO944704D0 (no
Inventor
Shingo Yano
Kazuo Ogawa
Masakazu Fukushima
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NO944704D0 publication Critical patent/NO944704D0/no
Publication of NO944704L publication Critical patent/NO944704L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Tiazolidin-derivat representert ved følgende formel (1): O hvor R1, R2 og R3 kan være de samme eller forskjellige og enkeltvis representerer et hydrogenatom, et halogenatom, en lavere alkylgruppe eller lavere alkoksylgruppe som kan være . substituert med ett eller flere halogenatomer, en hydroksyl- gruppe, en nitrogruppe, en aminogruppe, en lavere acylamino- gruppe, en mono- eller di-lavere-alkylaminogruppe, en karboksylgruppe, en lavere alkoksykarbonylgruppe, en cyano- gruppe, en 2-oksazolylgruppe, en tiazolidin-2,4-dion-5-yliden- metylgruppe eller en tiazolidin-2,4-dion-5-ylmetylgruppe og R1 og R2 kan være sammenkoblet under dannelse av en alkylenkjede -(CH2)P- hvor p står for 3, 4 eller 5 eller en alkylendioksy- kjede -O(CH2)qO- hvor q står for l, 2 eller 3 slik at det derved dannes en ring, R4 og R5 kan være de samme eller for- skjellige og enkeltvis representere et hydrogenatom eller en lavere alkylgruppe, X representerer et karbon- eller nitrogenatom; Y representerer et oksygenatom eller en imino- gruppe, A og B enkeltvis representerer en lavere alkylen- gruppe, m står for O eller l, og den stiplede linje angir tilstedeværelse eller fravær av en dobbeltbinding; et salt derav, en fremstillingsfremgangsmåte derfor; et farmasøytisk preparat som inneholder forbindelsen som en effektiv bestand- del; og en fremgangsmåte for behandling av diabetes ved administrering av forbindelsen. Forbindelsen ifølge den fore- liggende oppfinnelse har utmerket blodsukker-nedsettende virkning og blodlipid-nedsettende virkning, har god absorpsjon i kroppen og medikamentvirkning som varer lenge. Dessuten har den utmerket ekskresjon og har lav toksisitet mot det menneskelige legeme.
NO944704A 1993-04-07 1994-12-06 Tiazolidinderivater og farmasöytiske blandinger som inneholder disse NO944704L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8084693 1993-04-07
PCT/JP1994/000590 WO1994022857A1 (en) 1993-04-07 1994-04-07 Thiazolidine derivative and pharmaceutical composition containing the same

Publications (2)

Publication Number Publication Date
NO944704D0 NO944704D0 (no) 1994-12-06
NO944704L true NO944704L (no) 1995-01-30

Family

ID=13729720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944704A NO944704L (no) 1993-04-07 1994-12-06 Tiazolidinderivater og farmasöytiske blandinger som inneholder disse

Country Status (9)

Country Link
US (1) US5521202A (no)
EP (1) EP0645387A1 (no)
KR (1) KR0173145B1 (no)
AU (1) AU668818B2 (no)
CA (1) CA2135474C (no)
FI (1) FI945731A (no)
HU (1) HU224548B1 (no)
NO (1) NO944704L (no)
WO (1) WO1994022857A1 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
SK111195A3 (en) * 1994-09-13 1997-06-04 Sandoz Technology Ltd Bicyclic ethers substituted with oxazole and thiazole, process for producing thereof and pharmaceutical composition containing same
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
KR100429950B1 (ko) * 1995-07-31 2004-06-16 시오노기세이야쿠가부시키가이샤 포스포리파제에이2저해활성을갖는피롤리딘유도체
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5773629A (en) * 1996-06-14 1998-06-30 Industrial Technology Research Institute Synthesis of (4S, 5R) -2, 4-diphenyl-5-carboxy-oxazoline derivative as taxol side-chain precursor
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) * 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
ATE253903T1 (de) * 1996-12-11 2003-11-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
AU2823797A (en) * 1997-05-02 1997-11-19 Dr. Reddy's Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
TR200003595T2 (tr) 1998-06-05 2001-07-23 Astrazeneca Ab Kimyasal bileşikler
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
WO2002020515A1 (en) * 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
EP2125750B1 (en) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2141154A4 (en) * 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
JP5490014B2 (ja) 2007-12-11 2014-05-14 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の環状尿素阻害剤
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5734666B2 (ja) 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の1,3−オキサアゼパン−2−オン及び1,3−ジアゼパン−2−オン阻害剤
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2274287B1 (en) * 2008-03-18 2016-03-09 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5301563B2 (ja) 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2291373B1 (en) 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤
JP5390610B2 (ja) 2008-07-25 2014-01-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の合成
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター
TWI522109B (zh) * 2009-01-26 2016-02-21 臺北醫學大學 蕨素化合物用於治療糖尿病及肥胖之用途
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
WO2011149822A1 (en) 2010-05-26 2011-12-01 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン
AU2011325286B2 (en) 2010-11-02 2015-04-16 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI3141542T1 (sl) 2011-12-28 2020-11-30 Global Blood Therapeutics, Inc. Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
WO2014068397A1 (en) 2012-11-05 2014-05-08 Commissariat A L'energie Atomique Et Aux Energies Atlternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
SG11201507351PA (en) * 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EA028529B1 (ru) 2014-02-07 2017-11-30 Глобал Блад Терапьютикс, Инк. Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー,マモウン,エム. 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
JP2021518381A (ja) 2018-03-23 2021-08-02 エイドス セラピューティクス,インコーポレイティド Ag10を使用するttrアミロイドーシスの治療方法
US11260047B2 (en) 2018-08-17 2022-03-01 Eidos Therapeutics, Inc. Formulations of AG10
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN109867765A (zh) * 2019-02-28 2019-06-11 中山大学惠州研究院 一种长效缓释可降解防污聚氨酯及其制备方法
KR102674423B1 (ko) 2021-06-29 2024-06-13 (주)리스크제로 유체에 대한 실시간 지능형 모니터링 방법 및 그 시스템

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968707A (en) * 1987-06-10 1990-11-06 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
DE69228122T2 (de) * 1991-07-30 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo Neues bisheterocyclisches derivat und salz und hypoglykämische zusammensetzung

Also Published As

Publication number Publication date
EP0645387A4 (no) 1995-04-26
CA2135474A1 (en) 1994-10-13
NO944704D0 (no) 1994-12-06
HU9403491D0 (en) 1995-02-28
KR950701334A (ko) 1995-03-23
FI945731A0 (fi) 1994-12-05
US5521202A (en) 1996-05-28
WO1994022857A1 (en) 1994-10-13
CA2135474C (en) 1998-11-10
AU668818B2 (en) 1996-05-16
FI945731A (fi) 1994-12-05
AU6437394A (en) 1994-10-24
HU224548B1 (hu) 2005-10-28
HUT72308A (en) 1996-04-29
KR0173145B1 (ko) 1999-02-01
EP0645387A1 (en) 1995-03-29

Similar Documents

Publication Publication Date Title
NO944704L (no) Tiazolidinderivater og farmasöytiske blandinger som inneholder disse
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
FR2558162B1 (fr) Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
DK0870765T3 (da) Aminothiazolderivat, lægemiddel indeholdende samme og mellemprodukt til fremstilling af forbindelsen
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
NO20062101L (no) Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease
FR2669336B1 (fr) Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
MX9700763A (es) Procedimiento para la preparacion de benzoxazoles y derivados de piridinas utiles en el tratamiento de la diabetes del tipo ii, los benzoxazoles y derivados de piridina obtenidos, composiciones de los mismos y su uso.
NO305515B1 (no) 5-amino-8-metyl-7-pyrrolidinylkinolin-3-karboksylsyrederivater og farmas°ytiske preparater inneholdende disse
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
DE69110828D1 (de) Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
TW200608967A (en) Pharmaceutical compositions containing with diabetic agent
FR2612517B1 (fr) Derives de benzoxazine, procedes de preparation de ces derives et compositions pharmaceutiques les contenant
TW200616679A (en) Modified-release preparation
WO1998006400A3 (en) Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
NO323556B1 (no) Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter.
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
NO994764L (no) Nye pyridinderivater og farmasöytiske preparater inneholdende disse
EP1666472A4 (en) PHENYL ACETIC ACID DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
ES2070959T3 (es) Utilizacion de derivados del bis(4-hidroxifeniltio)metano en el tratamiento de la diabetes mellitus.
EA200000373A2 (ru) Новые соединения 1-аза-2-алкил-6-арилциклоалкана, способ их получения и содержащие их фармацевтические композиции
DK0410343T3 (da) Anvendelse af bisphenolderivater til behandling af diabetes mellitus
ATE278701T1 (de) Malto-oligosaccharide und deren verwendung
NO903084D0 (no) Farmasoeytisk anvendbare thiazol-derivater og fremgangsmaate for deres fremstilling.
DE3680893D1 (de) Pyrimido(5,4-b)(1,4)oxazinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel sowie zwischenprodukte darstellende pyrimido(5,4-b)(1,4)oxazinderivate.